Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Norovirus GI.1/GII.4 Bivalent VLP Vaccine · 1 trial · 1 indication
Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema swelling and induration.
Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema, swelling and induration.
Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.
Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.
The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).
The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
| Arm | Type | Description |
|---|---|---|
| Arm 1: NoV Vaccine Formulation A _1-Dose | EXPERIMENTAL | Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29. |
| Arm 2: NoV Vaccine Formulation A _2-Dose | EXPERIMENTAL | Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29. |
| Arm 3: NoV Vaccine Formulation B_1-Dose | EXPERIMENTAL | Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29. |
| Arm 4: NoV Vaccine Formulation B_2-Dose | EXPERIMENTAL | Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29. |
| Arm 5: NoV Vaccine Formulation A_1-Dose | EXPERIMENTAL | Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29. |
| Name | Type | Description |
|---|---|---|
| Norovirus GI.1/GII.4 Bivalent VLP Vaccine | BIOLOGICAL | Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection |
| 0.9% sodium chloride (saline) | DRUG | norovirus bivalent placebo-matching vaccine |
Inclusion Criteria: 1. Is aged 18 to 49 years, or 60 years and older at the time of enrollment; 2. Participants who are in good health, or in stable health status with no exclusionary medical or neuropsychiatric conditions at the time of entry into the trial as determined by medical history, physic...
The Norovirus GI.1/GII.4 Bivalent VLP Vaccine is an investigational vaccine developed by Takeda Pharmaceutical Company Limited for the prevention of norovirus infection. It is a bivalent virus-like particle (VLP) vaccine designed to target two norovirus genotypes, GI.1 and GII.4, which are associated with norovirus illness.
It is being developed for the prevention of norovirus infection. Norovirus is a leading cause of acute gastroenteritis worldwide. The vaccine targets norovirus GI.1 and GII.4 genotypes. It is investigational and has not been approved for use.
Takeda Pharmaceutical Company Limited (ticker: TAK) is the developer of the Norovirus GI.1/GII.4 Bivalent VLP Vaccine. Takeda is a global pharmaceutical company headquartered in Japan.
The Norovirus GI.1/GII.4 Bivalent VLP Vaccine is in Phase 2 clinical development. One Phase 2 trial has been completed. It is investigational and has not been approved by the FDA or any regulatory authority.
The vaccine has been studied in one completed Phase 2 trial, NCT02661490, titled "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population." The trial enrolled 320 participants in the United States and was randomized, double-blind, and controlled.